Influenza is estimated to be responsible for more than 226,000 excess hospital admissions annually in the United States. Sixty-three percent of all these hospital admissions occur among persons aged over 65 years, and the numbers of these hospitalizations have increased over the past decade. The risks for complications and death from influenza are highest among persons at the extremes of age and those with co-morbidities. In Hong Kong, the disease burden of influenza is substantial, and the associated mortality comparable to the Western countries. It has been estimated that up to 60 per 10,000 elderly individuals are hospitalized annually for influenza-associated complications such as pneumonia, exacerbation of COPD or asthma, and acute cardiovascular events. With an aging population, this creates a heavy burden on the healthcare system. In the first part of this lecture, clinical research on severe influenza infection conducted in the hospital setting will be discussed. Our studies show that influenza can result in serious complications, prolonged duration of hospitalization, and death. Timely diagnosis of influenza and initiation of antiviral treatment in the high-risk patients have significantly reduced their duration of hospitalization (by 33%) and mortality (odds ratio 0.26). Since 'cytokine storm' (e.g. IL-6, IL-8, IP-10 and MIG; mediated through signaling molecules such as p38 MAPK) is detected in these patients, and is triggered off by uncontrolled viral replication, early effective antiviral treatment may attenuate these deleterious responses, thus reducing patients' symptoms. In contrast to previously healthy subjects, these high-risk patients (mostly have significant comorbid illnesses) have persistently active viral replication and high viral loads beyond the first 2 days of illness; therefore, a slightly extended time window for antiviral treatment may be possible. Also, more stringent infection control measures may be necessary to avoid nosocomial outbreaks. In the second part of the lecture, research on the clinical diagnosis and management of severe communityacquired pneumonia (CAP) will be presented. Besides usual bacterial pathogens, respiratory viruses (e.g. influenza, RSV, SARS-CoV) and 'atypical pathogens' (e.g. mycoplasma, chlamydophila) are increasingly noted to be important causes of severe CAP. Utilization of certain clinical prediction rules to assist decisions on site-of-care (e.g. PSI, CURB-65), novel diagnostic markers (e.g. procalcitonin, neopterin), and choice of empirical antibiotic treatment will also be discussed. This emphasised to the world the key message of the importance of hand hygiene in reducing healthcare associated infections. The use of alcohol hand rubs are recommended to improve compliance amongst healthcare workers as the time spent in the activity is short and manageable, in contrast to hand washing. During SARS, high compliance in healthcare workers to hand hygiene was primarily driven by fear. However, the post-SARS period confirmed that this practice was not sustainable. Campaigns have been known to be a powerful and effective tool in changing behaviour and culture of a population. Countries that have used this tool successfully to achieve higher compliance in hand hygiene at a national level include USA, UK and Australia. We demonstrate equal level of effectiveness using the same principles and methodology at the institutional level. At the Singapore General Hospital, a 1600-bedded acute tertiary care hospital, several innovative means are adopted in its Hand Hygiene campaign since 2003. An objective validated hand hygiene audit tool in the form of the WHO tool gave good objective measurement of the baseline and the progress made during the campaign. Persistent strategic change was the prime objective of the campaign. Staff education and prominent cues to action were initial building blocks used in transforming behaviour. Patient involvement was engaged in a step-wise manner but its real impact has yet to be seen as it is still in its early days. The biggest impact was seen when hand hygiene became a clear institutional priority in the hospital's quality and patient safety arena. Leadership's support of the campaign through its visible presence, messaging and release of resources is the key factor in helping to make the campaign a true success.
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Background: 82 patients with SARS were admitted in ICU of Beijing Ditan Hospital last year. The clinical manifestations and outcomes of these patients were studied. Methods: 52 patients in acute stage and 30 patients in convalescent stage were observed. The examinations of routine laboratory, chest X-ray and immunocytes were done in all of patients; the series T-lymphocytes with its subtypes, the cytokines and RT-PCR for SARS virus were checked in part of patients; the bacteriological examination was done in patients with infection at acute or convalescent stage; the autopsy was performed in 4 died cases. Results: In acute stage, 10 patients had positive result of RT-PCR for SARS virus, the time of taking samples was 3 to 16 days after onset. In 2nd week, about 80% patients had the second peak of fever. As the same time or rather later, the patients with chest X-ray worsening were 65.4%, occurring dyspnea were 40.4%, and having ALI were 30.8%. In 3rd week, the 9 patients had a third peak of fever with the leukocytosis, their secondary infections were in-hospital infection. 8 cases were developed ARDS, and 7 cases were died. The autopsy found that lungs and immune system were severely damaged. There was a lowest peak of the lymphocyte and its subtypes at day 8 in mild and general type group. The lowest peak in severe type group was lower and later (4 days) than that in mild or general type group. In extremely severe type group, the lymphocyte subtypes kept in much lower level very long from day 12 to 28 and didn't recover in day 32. TNF-a, IL-6, INF-g, IL-2 and IL-4 were higher at day 4 6 and then decrease gradually; and IL-10 was higher from the second week. At convalescent stage, some patients remained interstitial pneumonia or diffuse pulmonary fibrosis; some patients had pulmonary cavities, pyothorax or pyohemothorax. Conclusion: The whole period of SARS could be divided into four stages: virus replacement stage, inflammatory injury stage, immunodeficiency stage and convalescent stage. The treatments must be applied on the characteristics of different stages.
